Infection
Update

Quinolones News

#3 May 2, 2017

Levofloxacin-containing triple therapy effective for treating refractory Helicobacter pylori infection

Since the discovery of Helicobacter pylori (H. pylori) in 1982, a large amount of research has gone into developing successful eradication strategies. However this task has grown increasingly difficult, due primarily to greater antibiotic resistance, creating a challenging clinical issue in both developed and developing countries.  To shed light on how best to manage patients after failure of first-line eradication therapy, researchers in Australia assessed the efficacy of salvage levofloxacin-based triple therapy.

In this prospective study, patients referred after prior treatment failure(s) were prescribed esomeprazole 40 mg, amoxicillin 1 g and levofloxacin 500 mg each twice daily for ten days. Evaluation of eradication was based on 13 C-urea breath test and/or histology and urease testing.
In 150 evaluable patients, main indications for treatment were peptic ulcer disease (17%), increased gastric cancer risk (20%), gastroenterological symptoms (35%) and other risk reduction (28%).

Results confirmed that the median number of failed prior therapies was 2 (range 1-7). Following treatment with the levofloxacin-containing salvage therapy, eradication of H. pylori was achieved in 90% and 91% of patients according to ITT and PP analysis, respectively. Researchers noted that the eradication rate did not change significantly when the number of prior treatment failures increased [(93% when ≤2 (n = 107), and 84% when 3 or more (n = 43; p = 0.13)] or with age, ethnicity, or reasons for starting treatment. However eradication rates were higher in females (ITT 94% v 82%, p = 0.04). Researchers found the levofloxacin-containing therapy to have a high compliance rate of 95%, due to excellent tolerability with no serious adverse effects and only mild adverse effects reported in 11%.

In conclusion, this levofloxacin-based triple therapy provides a useful salvage regimen in this region.

PMID: 28345276

Intern Med J. 2017 Mar 27. doi: 10.1111/imj.13432.

Source: https://w ww.ncbi.nlm.nih.gov/pubmed/28345276?dopt=Abstract

 
Return to Index


.

  ©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.
Disclaimer